Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Eero Rintala
Oct 01, 2021 11:11AM ET
this basicly same as ivermectin....
2
0
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data
Merck Soars After Potential Covid Drug Shows Lower Risk of Hospitalization, Death
© Reuters.
By Dhirendra Tripathi
Investing.com – Merck stock (NYSE:MRK) climbed more than 7% in Friday’s premarket trading after the company said trials of a drug it is developing against Covid showed reduced risks of hospitalization and deaths.
If approved, molnupiravir, the drug, could be the world’s first oral antiviral medicine for Covid, the company said in a note. Merck plans to seek emergency use authorization in the U.S. as soon as possible.
The company said the drug demonstrated consistent efficacy across viral variants Gamma, Mu and Delta, the most infectious of the lot.
The company is jointly developing the drug with Ridgeback Biotherapeutics.
The drug was administered to 775 patients in a phase-3 trial and at the time of the decision to stop the recruitment based on the interim efficacy results, the company said the trial was approaching full recruitment of the phase 3 sample size of 1,550 patients.
Eligibility criteria required that all patients had laboratory-confirmed mild-to-moderate COVID-19, with symptom onset within 5 days of study randomization. All patients were required to have at least one risk factor associated with poor disease outcome at study entry
Merck expects to produce 10 million courses of treatment by the end of 2021, with more doses expected to be produced in 2022. It will supply approximately 1.7 million courses to the U.S. government under an existing agreement, assuming all the approvals are in place.
Related Articles
Comments (2)
fenster fenster
Oct 01, 2021 9:58AM ET
Vaxart, Vxrt stock is the first oral against covid ..afaik
0
0
Kelly Mayer
Oct 01, 2021 9:58AM ET
please... c19early.com
1
1
Josh Davis
Oct 01, 2021 9:58AM ET
Kelly Mayer lol also dexamethasone was found be as or more effective but guess what thats a cheap drug that doesnt pad the pockets
1
0
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.